Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits ...

Teva Pharmaceuticals "pivot to growth" strategy under CEO Richard Francis aims to use a combination of biosimilars, generics, ...

Terns Pharmaceuticals aims to improve upon currently marketed therapies in CML and obesity, using internally discovered small ...

Reflecting on 20 years of experience working as a scientist in Big Pharma and biotech, Louise Modis, Ph.D., CSO at Amphista ...

The Biden administration, through policy and leadership appointments, raised the level of government scrutiny over ...

Paul Romness had over two decades of experience as a public and policy affairs expert when his daughter’s best friend’s osteosarcoma diagnosis inspired a new career trajectory.

Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.

In the world of biopharmaceutical innovation, groundbreaking scientific discoveries often do not directly translate into commercial success. Simply developing a promising therapeutic based on great ...